Dysbetalipoproteinemia: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) |
Usama Talib (talk | contribs) |
||
| Line 10: | Line 10: | ||
=Natural History, Complication, Prognosis= | =Natural History, Complication, Prognosis= | ||
==Complications== | ==Complications== | ||
Dysbetalipoprtenemia can cause the following complications <ref name="pmid12506591">{{cite journal| author=Blom DJ, Byrnes P, Jones S, Marais AD| title=Dysbetalipoproteinaemia--clinical and pathophysiological features. | journal=S Afr Med J | year= 2002 | volume= 92 | issue= 11 | pages= 892-7 | pmid=12506591 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12506591 }} </ref> | |||
* | * Atherosclerotic complications like ischemic heart disease | ||
*Pancreatitis | |||
* Stroke | * Stroke | ||
* Peripheral vascular disease | * Peripheral vascular disease | ||
Revision as of 19:20, 9 November 2016
Overview
Classification
Historical perspective
Pathophysiology
Causes
Differential Diagnoses
Epidemiology and Demographics
Screening
Natural History, Complication, Prognosis
Complications
Dysbetalipoprtenemia can cause the following complications [1]
- Atherosclerotic complications like ischemic heart disease
- Pancreatitis
- Stroke
- Peripheral vascular disease
- Intermittent claudication
- Gangrene of the lower extremities
Prognosis
- Patients with dysbetalipoproteinemia have an increased risk for coronary artery disease and peripheral vascular disease.
- With treatment, most people show a significant reduction in lipid levels.
Diagnosis
Diagnosis of dysbetalipoprotenemia is confirmed[2] by the
- Presence of a palmar crease xanthoma, which is a rare diagnostic finding of dysbetalipoproteinemia.
- Lipid profile
- Genotyping apoE
- Ultracentrifugation or nuclear magnetic resonance lipid profiling
History and Symptoms
Physical Exam
Laboratory Findings
Molecular Genetic Testing
Treatment
Medical Therapy
Dysbetalipoprotenemia can be treated[3] with
- Bile acid binding agents are an option if TG levels are <200mg/dL
- Statins can be used if TG levels are <500mg/dL
- Fibrates and Nicotinic acid can otherwise be used.
Prevention
- Screening the family members of those with familial dysbetalipoproteinemia may lead to early detection and treatment.
- Early treatment and avoiding other risk factors for vascular disease (such as smoking) are crucial to preventing early heart attacks, strokes, and blocked blood vessels.
References
- ↑ Blom DJ, Byrnes P, Jones S, Marais AD (2002). "Dysbetalipoproteinaemia--clinical and pathophysiological features". S Afr Med J. 92 (11): 892–7. PMID 12506591.
- ↑ Rothschild M, Duhon G, Riaz R, Jetty V, Goldenberg N, Glueck CJ; et al. (2016). "Pathognomonic Palmar Crease Xanthomas of Apolipoprotein E2 Homozygosity-Familial Dysbetalipoproteinemia". JAMA Dermatol. doi:10.1001/jamadermatol.2016.2223. PMID 27603268.
- ↑ Hachem SB, Mooradian AD (2006). "Familial dyslipidaemias: an overview of genetics, pathophysiology and management". Drugs. 66 (15): 1949–69. PMID 17100406.